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Abstract
The guideline provides a practical step-by-step guide in order to facilitate high 
quality echocardiographic studies of patients with aortic stenosis. In addition, it 
addresses commonly encountered yet challenging clinical scenarios and covers the 
use of advanced echocardiographic techniques, including TOE and Dobutamine 




Aortic valve stenosis is a significant health burden, particularly in older individuals, 
with a prevalence of up to 5% in individuals over 75 years of age1. Aortic stenosis is 
the most common valve disease necessitating surgical or percutaneous 
intervention2. Echocardiography is central in the diagnosis, assessment and 
management of individuals with aortic valve disease. The British Society of 
Echocardiography (BSE) has previously published a guideline document in order to 
facilitate high-quality echocardiography in the assessment of patients. This 
document is intended as an update to the previously published work.
This guide should be seen as supplementary to the BSE minimum dataset3. The 
intended benefit of this supplementary document is to:
 Support cardiologists, cardiac physiologists and clinical scientists to develop 
local protocols for the assessment of aortic valve disease.
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 Promote quality by defining the optimal methodology in the assessment of 
aortic valve disease and linking this to the current evidence-base.
 Ensure that the management of patients with aortic valve disease is based 
around contemporary data and optimal echocardiographic assessment. 
In some situations, this BSE guidance differs from the most recent European or 
American guidelines4-6. In those areas, these decisions were made in order to reflect 
contemporaneous data or as the result of differing interpretation. This guidance is 
divided into a number of subsections, which are listed in Table 1. 
1. Anatomy
The aortic valve usually consists of three cusps, suspended within the aortic root, 
which together form a gate between the left ventricular outflow tract (LVOT) and the 
aorta. Each cusp is usually associated with a specific out pouching or ‘sinus’ of the 
aorta: the left and right coronary cusps (LCC; RCC) are associated with the left and 
right coronary sinuses respectively, which are the usual point of origin of the left and 
right coronary arteries. The third or ‘non-coronary’ cusp (NCC) is associated with a 
sinus from which no arteries arise. Two thirds of the circumference of the aortic root 
is attached to the muscular interventricular septum. One third of the aortic root, 
which corresponds with the majority of the non-coronary cusp and a portion of the 
left coronary cusp, forms a fibrous continuity with the adjacent mitral valve (called 
the aorto-mitral continuity)7. Using echocardiography, normal anatomy of the aortic 
valve and aortic root is depicted in Figure 1. 
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 The BSE recommend that bicuspid valves (BAV) be described as either ‘antero-
posterior (AP)’ or ‘right-left (RL)’ orientation, with additional comment on the 
presence or absence of a raphe (see Figure 2)
 All patients with BAV should undergo a comprehensive assessment of the 
aorta to assess for dilatation and coarctation
 All patients with BAV should be offered echocardiographic surveillance
 Echocardiographic screening should be offered to first degree relatives of 
patients with BAV
BAV has a prevalence of between 0.5-1%8-10. Identification of BAV is important as 
they are disproportionately responsible for more advanced valve dysfunction and 
are associated with aortic dilatation11. The appearance and function of the valve at 
diagnosis are useful tools to inform discussions with the patient regarding prognosis 
and decisions concerning frequency of follow-up. Patients in whom the valve 
displays no thickening or calcification, and functions normally at baseline, have an 
excellent prognosis with fewer than 20% requiring aortic valve surgery over 20 years 
follow-up. Such individuals only require infrequent echocardiographic surveillance. 
Conversely, around 75% of patients with thickening, calcification or valve 
dysfunction will need surgery over a similar timeframe and therefore should be 
monitored more closely12,13. 
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Differing classifications of BAV have been advocated in the literature, which means 
that comparisons and nomenclature are not standardized14-17. Importantly, there is 
no consensus as to associations between the sub-type of BAV and the pattern of 
valve dysfunction or aortic dilatation14-16. 
Where there is uncertainty about the potential diagnosis of BAV, this should prompt 
review of any past echocardiographic images and consideration of advanced imaging 
techniques (i.e. TOE) to resolve the uncertainty, given the importance of the 
diagnosis for long-term prognosis. 
Unicuspid and quadricuspid aortic valves
Key points
 Unicuspid valves (UAV) may display advanced aortic stenosis in the absence 
of heavy calcification 
 Patients with UAV and severe AS should be intervened upon according to 
standard indications in international guidance
Less common anatomical variants are also recognized, which include quadricuspid or 
unicuspid aortic valves (QAV; UAV). Quadricuspid aortic valves are rare, with an 
estimated prevalence of <0.01%18. There is an association between QAV and aortic 
dilatation, and the predominant valve lesion is that of regurgitation, with stenosis a 
less frequent presentation18,19.  
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The estimated prevalence of UAV is around 0.02%20. Transthoracic (TTE) and trans-
oesophageal echocardiography (TOE) are both highly specific for the identification of 
UAV, but are poorly sensitive, with unicuspid valves often mistakenly identified as 
bicuspid particularly in the presence of marked calcification21. Unicuspid valves are a 
disproportionate contributor to the overall burden of severe aortic stenosis, 
particularly in young individuals11,22. An example of UAV is in Figure 3. 
2. Calcification and aetiology of AS
Key points
 Calcification is central to the development of aortic stenosis
 Echo studies should describe the pattern and burden of calcification
 Echo studies should identify thickening of cusps and restriction of motion
 In the absence of significant calcification, important aortic stenosis should 
not usually be considered
There are three main aetiological factors contributing toward the development of AS 
within the UK. BAV is described above. Rheumatic heart valve disease is the most 
frequently seen worldwide but is rare in the UK. Rheumatic AS is characterized by 
calcification affecting the margins of the cusps and commissures, with relative 
sparing of the body of the cusps. Rheumatic aortic valve disease is almost never seen 
in the absence of mitral stenosis (MS)4. 
The commonest cause of AS in the UK is age-related calcific degeneration of the 
valve, which is characterized by progressive thickening, fibrosis and calcification of 
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the aortic cusps. Such patients often display an abundance of calcification at the 
base of the cusps, whereas the commissures tend to be spared. Risk factors for 
calcific degenerative AS include hypertension, dyslipidaemia, smoking, diabetes and 
impaired renal function23,24. 
3. Haemodynamic principles of aortic stenosis
The normal aortic valve is compliant and opens fully, and presents almost no 
obstruction to blood flow out of the heart during systole. With worsening aortic 
stenosis, the valve becomes progressively more restricted, and consequently aortic 
valve maximal velocity (Vmax) and mean gradient (AVG) are correspondingly higher. 
Importantly, as blood approaches a fixed obstruction, it accelerates prior to the point 
of maximal obstruction, which has implications when estimating flow within the LV 
outflow tract (Figure 4)25-28. As blood accelerates, the jet additionally ‘contracts’ in 
order to fit through the narrowed aortic orifice29. It may be assumed that once the 
jet has passed the valve it will immediately expand to fill the aorta, but in fact the jet 
continues to contract for a short distance, forming a vena contracta. This vena 
contracta represents the ‘effective orifice area’ which is always smaller that the 
‘anatomic’ orifice area. This principle is important, as, whilst it is the anatomical 
valve area that is responsible for the flow obstruction, the effective orifice area is the 
key determinant of survival and long-term outcomes in patients with aortic stenosis 
(Figure 4)29. Maximal AV velocity, mean gradient and the estimated aortic valve area 
(AVA) using the continuity equation all assess the haemodynamic impact of the 
effective orifice area and as such are useful for the determination of prognosis30,31. 
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4. Standard echocardiographic images
In all patients with aortic valve disease, it is imperative that they undergo a complete 
and careful echocardiographic evaluation, according to the principles of the 
minimum dataset3 . The specific windows and images required for the 
echocardiographic assessment of AS are described in Table 2 followed by a 
suggested reporting template in Table 3. 
5. Essential parameters in the echocardiographic assessment of AS severity
Aortic valve maximal velocity and mean gradient
Key points 
 AV Vmax and mean gradient should be obtained in all patients undergoing 
the assessment of aortic valve stenosis
 The standalone or PEDOFF probe should be used in all patients from multiple 
acoustic windows
 AV Vmax and mean gradient should be combined with the aortic valve area in 
order to describe AS severity 
 BSE recommended methodology is demonstrated in Figure 5
Maximal AV Velocity and mean gradient are both obtained using continuous wave  
(CW) Doppler interrogation of the aortic valve (see Figure 5)32,33. 
The simplified Bernoulli equation (Box 1) is a formula by which the maximal velocity 
across an aortic valve can be ‘converted’ to an equivalent pressure change. There is 
no specific benefit of describing a peak gradient defined using echo over and above 
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the maximal AV velocity, but an appreciation of the method is of value, as is an 
understanding of clinical scenarios in which CW Doppler may result in under- or 
over-estimation of AS severity. 
The major challenge with CW Doppler is ensuring that the angle of insonation is fully 
aligned with the direction of the AS jet. A difference in alignment of more than 15-
20 between the ultrasound beam and the direction of blood flow will result in 
significant underestimation of Doppler indices and the severity of AS27,32. Sometimes 
this underestimation may be obvious to the sonographer, however, often traces may 
appear adequate only for further interrogation to demonstrate significantly higher 
values than first obtained (Figure 5). 
Box 1
Simplified Bernoulli equation:
Pressure difference = 4 ×  (𝑉22 ―  𝑉12)
Where V2 is the velocity of blood flow across the obstruction, and V1 is the velocity 
of blood flow prior to the level of obstruction. In most patients V1 is relatively small 
(≈1m/s or lower) and is therefore negligible in the context of high values of V2. 
Consequently, the formula can be simplified further:
Pressure = 4 × 𝑉2
In circumstances where the sub-valve velocity is unexpectedly high (i.e. with small 
calibre LVOT dimensions or dynamic outflow tract obstruction), the longer equation 
(top) should be used. 
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Mean AVG is derived from an assessment of the average of the instantaneous 
velocities occurring during systole and is obtained from tracing around the CW 
Doppler waveform obtained through the aortic valve (see Figure 5). Calculating the 
mean AVG is complex and is not derived from the mean velocity, but is routinely 
performed by measurement packages pre-installed on imaging platforms. Deriving 
the mean AVG utilizes the Bernoulli equation, and as such there are two important 
considerations when obtaining and interpreting this parameter. Firstly, owing to the 
squared relationship between instantaneous velocity and gradient, any under-
estimation of the CW Doppler waveform will lead to an exaggerated 
underestimation of the mean gradient. Secondly, in the case of sub-valve 
obstruction and increased LVOT velocity, both the mean gradient and maximal 
velocity will overestimate severity of valvular stenosis. Other methods to assess AS 
severity will need to be employed in this scenario. 
Recommended methodology (Figure 5)
 It is essential to use multiple echocardiographic windows. Whilst in the 
majority of patients maximal values for AV Vmax and mean AVG are obtained 
from the apical window, in 20% of cases it is the suprasternal or right 
parasternal window that provides optimal results26,27.  
 The BSE recommends use of the PEDOFF or standalone probe in all patients. 
 The traces should be optimized for gain and scale. Sweep speed should be set at 
50-100mm/s. 
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 At least three beats should be averaged for patients in sinus rhythm with a 
minimum of 5-10 consecutive beats for patients in AF (see section 9 for details 
and alternative methodology). 
 The dense outer edge of the spectral waveform should be traced. Transit time 
artefact (which appears as a spectral dispersion or ‘blurring’ at the peak of the 
curve) should be ignored and not included within the trace (Figure 5). The 
‘reject’ function of the echo machine helps reduce transit time artefact and 
better delineate the modal signal. 
 The shape of the CW waveform can provide an insight into the severity of AS. 
The CW curve in patients with moderate stenosis often has a rapid early peak, 
whereas severe AS will often display a slow acceleration with late peaking 
waveform4 (Figure 6). 
 The echocardiographic report should include the AV Vmax, the mean gradient, 
the window and transducer with which the maximal values were obtained. 
Aortic valve area 
Key points 
 The effective aortic valve area, calculated using the continuity equation, 
should be obtained in all patients undergoing assessment of AS 
 The AVA should be combined with the AV Vmax and mean gradient in order 
to describe AS severity 
 The LVOT diameter should be measured at the insertion point of the aortic 
cusps and not below
 BSE recommended methodology is demonstrated in Figure 7
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The assessment of AVA is well validated using echocardiography and is an essential 
aspect of the comprehensive echocardiographic assessment of AS25-28. The 
continuity equation is used to estimate the AVA, and is outlined in Box 2. 
Box 2
The continuity equation dictates that the volume of blood flowing through the LVOT 
must be the same as the volume of blood flowing through the aortic valve. We can 
calculate stroke volume in any conduit as the product of the velocity-time integral 
and the cross-sectional area (CSA) of the conduit. Using these two principles, we can 
derive the following formulae:
Aortic valve stroke volume = LVOT stroke volume
AV VTI × AV effective orifice area =  LVOT VTI × LVOT CSA
Therefore:
AV effective orifice area =  
LVOT VTI × LVOT CSA
AV VTI
The LVOT is assumed to be circular; therefore the LVOT CSA is replaced by:
LVOT CSA =  π ×  (LVOT diameter2 )
2
A ‘simplified’ continuity equation using velocity rather than the VTI is not 
recommended and is more prone to error, with a tendency to overestimate the 
calculated valve area25. 
Calculated AVA is useful as it is far less sensitive to alterations in transvalvular flow, 
and therefore will provide a more stable assessment of AS over a range of 
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haemodynamic states28,34,35. Conversely, estimated AVA requires several detailed 
measurements and is therefore more susceptible to technical error. 
In an ideal scenario, both the LVOT Velocity Time Integral (VTI) and the LVOT cross 
sectional area would be obtained at the same anatomical level. However, to all 
intents and purposes this is impossible. The two measurements are acquired from 
different echocardiographic windows, and so the sonographer can never be sure 
whether they are being obtained ‘at the same point’. More importantly, there is 
significant axial motion (up to 1cm) of the aortic annulus during systole25. 
Additionally, as mentioned previously, blood flow within the LVOT accelerates prior 
to the stenotic valve within the zone of acceleration, which can extend up to 1cm 
from the anatomical annulus25 (see Figure 4). As such, even if the cross-sectional 
area and VTI were obtained at the same anatomical level, it would not necessarily be 
truly representative of stroke volume. 
Recommended methodology (Figure 7)
 Maximal AV velocity and mean gradient should be obtained using CW recordings 
as outlined in the previous section from multiple echocardiographic windows 
using the standalone probe. The maximal values obtained (an average of three 
beats) should be used in the continuity equation irrespective of which window 
the CW tracings were obtained from. 
 The LVOT diameter should be measured at the point of insertion of the aortic 
cusps, using an inner-edge to inner-edge methodology from the parasternal 
long-axis window (not the apical windows). This recommendation differs from 
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historical practice whereby the LVOT has often been measured up to 1cm below 
the point of insertion of the cusps. This approach is no longer recommended by 
the BSE. 
 Measuring the LVOT diameter at the point of cusp insertion improves inter-
observer reproducibility, better corresponds to the ‘true’ AVA derived using 
invasive tools, and provides a more accurate assessment of the cross-sectional 
area, as the LVOT is usually circular at this anatomical level25-27. 
 It is essential that all sonographers within a department use the same 
methodology to measure the LVOT diameter. 
 In departments where the LVOTd was previously measured below cusp 
insertion, it is important to highlight to the referring clinician that the 
methodology has been updated. We would recommend that the report includes 
the following statement: 
- The AVA is now being estimated in accordance with updated BSE 
guidance 2021. Changes in the estimated AVA from previous studies 
should therefore be interpreted with caution.
 Care should be taken to exclude eccentric calcification from the measurement 
(see troubleshooting section below). 
 The LVOT diameter should not be ‘assumed’ to be 2cm. Careful measurement of 
the LVOT diameter will provide a better assessment of true AS severity27. 
 For follow-up studies, it is important to note any changes in the measured LVOT 
diameter as this will dramatically impact on reported AVA. If there is a marked 
change in LVOT diameter, careful review of the previous and current study in 
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order to establish an accurate value is required.  In such cases re-reporting the 
earlier study is essential in order to document interval change accurately. 
 The PW trace should be obtained by placing the sample volume on the valve, at 
which point ‘aliasing’ will be noticed, reflecting rapid flow through the stenosed 
valve. The PW sample volume should then be slowly withdrawn apically until a 
suitable trace is obtained (Figure 7).  
 The recordings should be optimized for gain and scale to improve accuracy. The 
sweep speed should be set between 50-100mm/s. Three consecutive 
waveforms should be measured and averaged for patients in sinus rhythm, with 
a minimum of 5-10 consecutive waveforms measured in AF (see section 9 for 
details and alternative methodology). 
 LVOT waveform should have a well-demarcated, narrow band of recorded 
velocities throughout systole. If any spectral dispersion or transit time artefact 
(‘blurring’) of the trace is noted, the PW sample volume should be moved more 
apically (i.e. away from the valve). 
 The process of obtaining PW traces should be repeated in both the apical 5- and 
3-chamber windows. The maximal LVOT VTI obtained (as an average of three 
beats) should be used in the continuity equation. 
 Patients in whom accurate assessment of the LVOT dimensions cannot be 
obtained (for example owing to poor echocardiographic windows) the 
calculation of AVA using the continuity equation should be abandoned, in which 
case other parameters should be used to determine AS severity. 
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Box 3: Common errors in assessment of AS
1. Failure to use PEDOFF probe from multiple acoustic windows including apex and 
right intercostal space. 
2. Inaccurate assessment of LVOT diameter and cross sectional area
 - Calcification must be excluded
 - Measure LVOT diameter at the level of cusp insertion
 - Remember non-circular nature of LVOT
3. Poor positioning of PW sample volume.
4. Failure to image the ascending aorta and arch
Potential sources of error and troubleshooting 
 Underestimation of maximal AV velocity and mean gradient owing to sub-
optimal alignment of the Doppler transducer. This source of error will directly 
lead to an underestimation of AS severity. 
 Underestimation of LVOT cross-sectional area. If the LVOT diameter is 
underestimated, this will lead to an exaggerated underestimation of the cross-
sectional area owing to the squared relationship between the two. Eccentric 
calcification of the LVOT is a major source of error in this regard. This type of 
error will directly result in an overestimation of AS severity. 
In many circumstances, the LVOT is elliptical rather than circular. The standard 
method of calculating the LVOT CSA will therefore significantly underestimate 
the true value, resulting in an overestimation of AS severity. On such occasions 
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direct planimetry of the LVOT cross-sectional area may improve accuracy (see 
section 12). 
Examples of these sources of error are depicted in Figure 8-9. 
 Positioning of PW sample volume:
The measurement of flow using PW Doppler is highly dependent on the position 
of the PW sample volume. If the sample volume is positioned too close to the 
valve, increased velocity from the zone of acceleration will be included. This will 
directly lead to an underestimation of AS severity. 
Conversely, if the PW sample volume is moved too far apically (i.e. away from 
the valve and into the LV cavity), the obtained LVOT VTI will frequently 
underplay ‘true’ stroke volume and lead to overestimation of AS severity. 
In cases where the LVOT is short, withdrawing the PW sample from the valve to 
obtain a suitable LVOT Doppler tracing may result in a rapid reduction in 
velocities. In this scenario, 3D imaging of the LVOT closer to the anatomical level 
at which the PW trace was recorded may improve accuracy (Figure 9). 
6. Approach to the patient
Figure 10 describes the echocardiographic approach to classifying the severity of AS 
and identifying high-risk characteristics. This will allow the majority of patients to be 
consistently graded and ensure that important prognostic findings are highlighted to 
the clinician. 
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 The first priority in the assessment of AS is to ensure that the valve is both 
calcified and restricted. In the absence of either of these, significant AS is 
unlikely except in the (rare) circumstance of congenital AS. 
 Next, ensure that a robust assessment of both maximal AV velocity and mean 
gradient have been obtained. If either the AV Vmax is ≥4m/s or the mean AVG is 
≥40mmHg, the patient should usually be considered as having severe AS. The 
rare exceptions to this are in circumstances in which there is temporary increase 
in flow such as tachy-arrhythmia or sepsis, in which case repeat assessment 
when the haemodynamic status has normalized should be considered. 
 Once AV Vmax is noted to be ≥4m/s or the mean AVG is ≥40mmHg, the focus of 
the study should then turn to assessing for the high-risk characteristics that 
define prognosis and may inform clinical decision-making (see Box 4 and section 
10). 
 If AV Vmax and mean AVG do not fulfil the criteria for severe AS, assessment of 
the AVA will usually confirm that the patient has non-severe AS (i.e. the AVA will 
be ≥1cm2). In this scenario the severity of AS should be defined using the AV 
Vmax or mean gradient (whichever is the greater; Table 4). 
 If, however, the Vmax and/or mean AVG suggest non-severe AS but the AVA is 
<1cm2, further thought is required (Figure 10). It is imperative to re-check all 
measurements, in particular ensuring that the PEDOFF probe has been used 
from multiple echocardiographic windows. Assessment of the shape of the CW 
waveform may provide a clue as to the underlying severity (see Figure 6). For 
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individuals of small body habitus (i.e. a BSA <1.7m2), use of the indexed AVA 
may confirm that the severity is moderate (see section 8 for details of indexed 
AVA). 
 There is not a linear relationship between Doppler indices and the AVA. Often, 
the Vmax or mean gradient will fall in the range of 3.5-4m/s or 35-40mmHg 
respectively, at which point the AVA will likely be between 0.8-1.0cm2. Such 
patients are usually best treated as being ‘moderate AS’ but are often 
pragmatically reported as ‘moderate to severe AS’ to ensure that the advancing 
nature of the disease is highlighted to the clinician. 
 If a marked disagreement between the Doppler indices and AVA remains, the 
next stage is to refer to ‘special circumstances’ (section 12). An MDT approach 
for challenging cases is advocated and ensures consistency within a department. 
7. Grading of severity
Aortic sclerosis
Key points
 Aortic sclerosis is defined as a thickened restricted aortic valve without 
significant obstruction to flow
 AV Vmax is <2.5m/s
 Echocardiographic surveillance is not routinely recommended
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The prevalence of aortic sclerosis increases with age, and is associated with 
hypertension, renal disease, dyslipidaemia, and smoking23. Approximately 2% of 
patients per year will progress from aortic sclerosis to aortic stenosis36, and as such it 
is important to identify these patients so they can have any risk factors addressed. In 
some clinical scenarios surveillance may be considered, such as younger individuals 
with risk factors such as advanced renal dysfunction. 
Mild, moderate and severe AS
Key points
 Maximal velocity is the preferred measure with which to define AS severity
 The echocardiographic report should document the change in maximal 
velocity with time
 Echocardiographic surveillance is advised6: 
- Mild AS (Vmax <3m/s) repeated every 3-5 years
- Moderate AS (Vmax 3-3.9m/s) repeated every 1-2 years
- Severe AS (Vmax ≥4m/s) repeated every 6 months
A wealth of prospective data has demonstrated the association between AV Vmax 
and cardiovascular events30,37-40. Fewer than 30% of patients with an AV Vmax <3m/s 
will need aortic valve intervention within 5 years of follow-up30,38. If the AV Vmax is 
between 3-4m/s, around half of patients will need surgery within 4 years. As the 
maximal velocity increases, so time-to-event decreases30,37,39. AVA is a useful tool to 
assess AS severity, but there are relatively few studies in the literature 
demonstrating an independent association between adverse survival and AVA, with 
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most data suggesting that the AVA cut-off for predicting poorer outcomes is 
0.8cm241,42. 
In patients with heavily calcified valves, a change in AV Vmax of >0.3m/s/year is 
associated with poor outcomes30,37.  Accordingly, the rate of change in AV Vmax 
should be documented in the echo report and can be calculated by dividing the AV 
Vmax change by the appropriate decimal (i.e. 6 months = 0.5).  Changes in AV Vmax 
should only be interpreted if sequential studies obtained maximal velocity from 
similar echocardiographic windows. It is important to review previous studies and 
ensure that any change in AV Vmax is not related to the measurement of artefact. 
Very severe AS
Key points
 Very severe AS is defined as an AV Vmax ≥5m/s or a mean gradient 
≥60mmHg 
 Patients with very severe AS have poor event-free survival even in the absence 
of symptoms. 
 Such patients should be highlighted to the referring physician. 
Very severe AS describes patients who display either very high gradients or very 
small aortic valve areas, associated with particularly poor outcomes. Once the AV 
Vmax is ≥5m/s, survival is reduced even in the absence of symptoms40,43,44. Similarly, 
a mean gradient ≥60mmHg and an AVA ≤0.6cm2 are associated with extremely high 
event rates and largely correspond with an AV Vmax of 5m/s45-47. American 
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guidelines advocate surgery in such patients even in the absence of symptoms (Class 
IIa indication)6.
The BSE discourages use of the term ‘critical AS’ as it is not clearly defined within the 
literature48-51.  
8. Additional parameters in the assessment of aortic valve stenosis
These additional parameters are not usually required in every patient, but 
occasionally may provide additional clues as to the severity of the AS, or may be of 
use in certain clinical scenarios. 
Indexed aortic valve area 
Key points
 The indexed AVA (AVAi) is not required in all patients
 An AVAi <0.6cm2/m2 is consistent with severe AS
 In individuals of small body habitus (i.e. a BSA <1.7m2), the AVAi may re-
classify some individuals as having moderate AS, potentially avoiding 
unnecessary intervention (see Figure 10)
 The AVAi should be avoided in patients who are overweight, where AVAi will 
overestimate AS severity
Indexed aortic valve area was introduced in the 1960s to account for the large 
proportion of paediatric patients with AS52. AVAi is not superior to absolute AVA in 
the assessment of individuals and identification of high risk42,53. Patients who are 
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considered to have severe AS solely on the basis of an AVAi (i.e. an AVAi of 
<0.6cm2/m2 but an AVA ≥1cm2) have significantly better outcomes than individuals in 
whom the absolute valve area is <1cm253. 
The AVAi should usually only be employed in individuals of small body habitus (i.e. a 
BSA <1.7m2) in whom the AVA implies severe AS but where AV Vmax or mean AVG 
suggest the valve is non-severe (i.e. an AVA <1cm2; Vmax <4m/s and mean AVG 
<40mmHg): in such patients the AVAi may re-classify AS severity as moderate, 
thereby avoiding unnecessary intervention (see Figure 10)53,54. 
Dimensionless index
Key points
 The Dimensionless Index (DI) is obtained from the ratio of LVOT: AV velocities. 
A value of <0.25 is consistent with severe AS
 The DI is useful when image quality prevents accurate assessment of the 
LVOT cross-sectional area
 If the LVOT cannot be measured accurately, DI may be used for serial studies 
to monitor progression of AS
The DI removes one potential source of error (measurement of the LVOT cross-
sectional area), but does not account for the true anatomy of the LVOT, and is 
usually less accurate than the AVA in the assessment of AS severity25-27. If 
parasternal windows are challenging such that accurate assessment of the LVOT 
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diameter cannot be obtained, the DI is useful, and may be used for surveillance. 
Once the DI is <0.2, outcomes are very poor, independent of the patient’s BSA55. 
Planimetry
Key points
 The BSE does not recommend routine use of planimetry
 If planimetry is to be pursued, TOE is the echocardiographic modality of 
choice, and 3D imaging improves accuracy
 Flow contraction means that planimetry always underestimates AS severity 
even if performed accurately (see Figure 4)
 Planimetry is not reliable in low-flow states as there is insufficient opening of 
the valve
Planimetry is a technique whereby the anatomical orifice of the aortic valve is 
directly traced in order to provide an estimation of the AVA (Figure 11). 
There are multiple pitfalls to this technique. The imaging plane must be aligned with 
the point of maximal stenosis of the valve. Identifying the aortic orifice is challenging 
in heavily calcified valves in which blooming artefact will result in potential 
overestimation of severity. Whilst planimetry is feasible and correlates with Doppler-
based estimates of AS severity, the limits of agreement are poor which restricts the 
value of this technique in clinical decision-making56-58. 
Energy loss index
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Key points
 The energy loss index (ELI) accounts for the pressure recovery phenomenon
 The BSE does not recommend routine use of the (ELI)
 An ELI <0.6cm2/m2 is consistent with severe AS
As blood flows past an obstructed aortic valve, the velocity of blood increases, and 
static energy (or pressure) is converted into kinetic energy. This manifests as a 
pressure drop. As blood flow continues beyond the obstructed valve into the aorta, 
some kinetic energy is converted back into static energy and a proportion of 
pressure is restored. Standard echocardiographic parameters of AS severity do not 
incorporate the effect of the ‘pressure-recovery’ phenomenon. 
The ELI is a way to calculate a ‘corrected’ valve area that accounts for pressure-
recovery, which is reported after indexing for BSA59. The ELI will only ever re-classify 
a valve as being less severe than suggested by standard Doppler indices. Use of the 
ELI has been validated in observational studies and a randomized trial and 
occasionally re-classifies the severity of observed stenosis, but overall performs no 
better than traditional measures of AS severity at identifying individuals at risk31,60,61.  
Patients with a mean AVG >40mmHg should be considered as having severe AS and 
not re-classified as moderate AS using the ELI. The ELI may be considered in patients 
with low-gradient AS (i.e. an AVA <1cm2; Vmax <4m/s and mean AVG <40mmHg): in 
such scenarios, the ELI can identify a subset of individuals who are at lower risk and 
can afford to be observed60,61. A worked example of the ELI is in Figure 12. 
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9. Other considerations
Atrial fibrillation or irregular rhythms
Key points
 In patients with AF, average values from 5-10 consecutive beats are required 
to ensure accurate assessment of AS severity
 An alternative methodology is the matched R-R interval approach (Figure 13)
 LVOT VTI should not be derived from the inner envelope LVOT seen within CW 
tracings (Figure 13)
For patients in AF, Doppler indices from at least 5 consecutive beats should be 
measured, from which the average AV maximal velocity, mean gradient and 
calculated AVA are derived4. There is mixed evidence in the literature as to the 
number of consecutive beats required, with some studies reporting that, on average, 
13 consecutive beats are needed to approximate the true cardiac output for a 
patient with AF, whereas other work has demonstrated that there appears to be 
minimal variation of the calculated AVA in patients with varied R-R intervals62,63. 
An alternative method is to obtain Doppler recordings for AV VTI and LVOT VTI from 
matched cycle lengths. The method involves recording a single AV VTI measurement 
after a long R-R cycle, combined with a single LVOT VTI measurement obtained after 
a similar long R-R cycle length (where ‘long R-R’ is defined relative to the average 
heart rate; Figure 13). These two single measures can then be used in the continuity 
equation to derive the calculated AVA. This methodology has shown to correlate 
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highly with the traditional method of valve area calculation, with high degrees of 
reproducibility64. 
It is often possible to see an approximation of the LVOT trace within the continuous-
wave Doppler recordings through the AV (Figure 13). These phantom tracings should 
not be used in the continuity equation as they systematically overestimate the 
calculated stroke volume as higher velocities from the flow convergence region are 
included within the trace, and would result in underestimation of severity of aortic 
stenosis using the continuity equation63. 
Blood pressure
Key points
 Hypertension may lead to either over- or under-estimation of AS severity
 In challenging clinical situations AS should be re-evaluated after adequate 
control of BP: target of 130-140mmHg (systolic BP)
Assessment of AS is challenging in patients with poorly controlled hypertension, 
owing to the complex inter-relationship between systemic BP, afterload, 
transvalvular flow and indices of AS severity. In one study, systemic vascular 
resistance was acutely increased through the use of infused adrenaline or isometric 
handgrip exercise, which led to a reduction in calculated aortic valve area, although 
mean pressure gradient was relatively unchanged65. Conversely, an experimental 
study in pigs created a hypertensive state by banding the aorta, which resulted in an 
acute reduction in the mean pressure gradient combined with increased calculated 
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valve areas66. Both these studies use experimental methods to mimic a hypertensive 
state and therefore are unlikely to reflect the vascular, morphological and 
haemodynamic alterations seen in patients with long-standing hypertensive heart 
disease. In fact, a study in which a circulatory model was used to examine the effect 
of blood pressure on Doppler indices of AS suggested that BP alterations per se did 
not lead to predictable changes in mean gradient or calculated valve area, but that 
alterations in transvalvular flow were responsible for the variations noted67. 
Poorly controlled hypertension in the context of AS is associated with worse 
survival68. Historically, anti-hypertensive agents have been considered relatively 
contra-indicated in the presence of significant AS, but in fact most are tolerated well 
and appear safe69. There is some evidence that calcium-channel blockers (CCBs) are 
associated with poorer outcomes and an adverse BP response to exercise70,71. 
Therefore, it is reasonable to use alternative anti-hypertensive agents where 
feasible72,73. In particular, ACE-inhibitors or other agents targeting the renin-
aldosterone system are not only effective and well tolerated in AS, but improve long-
term prognosis69. 
10. Additional prognostic markers
The following sections outline additional echocardiographic parameters that are 
useful in assessment of risk and clinical decision-making. These sections refer to 
patients in whom an AV Vmax ≥4m/s and/or mean AVG ≥40mmHg have been 
obtained. Box 4 lists the prognostic findings that should be highlighted to the 
referring clinician. 
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Box 4: Prognostic findings in severe AS (AV Vmax ≥4m/s or mean AVG ≥40mmHg) 
Highlight to referring clinician
1. Very high gradients (very severe AS): AV Vmax ≥5m/s; mean gradient ≥60mmHg 
2. Rate of change of AV Vmax: heavily calcified valve with increase of >0.3m/s/year
3. Left ventricular ejection fraction <55%
4. Global longitudinal strain (GLS) >-14; (GLS is encouraged but not mandated)
5. Increased indexed LV mass: >110g/m2 (males) or >99g/m2 (females)
6. High likelihood of pulmonary hypertension
Left ventricular ejection fraction
Key points
 LVEF should be assessed in all patients with aortic stenosis using quantitative 
methodology if possible
 Patients with severe AS (Vmax ≥4m/s and/or mean gradient ≥40mmHg) and 
an LVEF <55% should be reported as ‘impaired LVEF’ in the clinical report
 Patients with severe AS (Vmax ≥4m/s and/or mean gradient ≥40mmHg) with 
an LVEF ≤35% should be reported as ‘severely impaired LVEF with high 
likelihood of improvement after aortic valve intervention’
Severe AS with a mean gradient ≥40mmHg and an LVEF <50% is encountered 
infrequently in clinical practice74,75. Usually this scenario reflects an afterload 
imbalance whereby inherent contractility is largely preserved, and LVEF will typically 
improve after aortic valve intervention51,76. Such individuals are noted to have poor 
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outcomes without surgery and accordingly it is a Class I indication for aortic valve 
intervention5,6. 
Patients with an LVEF <55% have significant excess mortality compared to those in 
whom the LVEF is >60%, independent of whether surgery is undertaken77. Outcomes 
for patients undergoing AVR with an LVEF between 55-60% may also be worse than 
those undergoing surgery with an LVEF>60%75. Database analyses have suggested 
that rapid reduction in the LVEF of more that 10% per year appears to be associated 
with poorer survival in patients with asymptomatic severe AS78. 
Indexed LV mass
Key points
 Indexed LV mass (LVMi) should be reported for all patients with severe AS
 LVMi should be estimated using the linear method from the parasternal long-
axis window and indexed to BSA3
- For males an LVMi >110g/m2 is abnormal
- For females an LVMi >99g/m2 is abnormal
Part of the adaptive mechanism of the left ventricle to an increased afterload is 
compensatory hypertrophy. This leads to normalization of wall stress and 
maintenance of cardiac output79,80. Whilst there are mechanistic benefits of 
hypertrophy in patients with aortic stenosis, it is also recognized that excessive 
indexed LV mass can result in increased myocardial oxygen demand, myocardial 
fibrosis, and increased cardiovascular mortality81,82. 
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 Global longitudinal strain (GLS) may identify patients who are at an increased 
risk of cardiovascular events
 The BSE encourages the assessment of GLS in patients with AS where image 
quality allows
 Significant inter-vendor variability exists for GLS, but a value more positive 
than -14% is very likely indicative of LV dysfunction
Early changes in LV performance may not result in reduction in measured LVEF, and 
yet will confer worse prognosis on such patients. Global longitudinal strain (GLS) 
derived using speckle tracking is a surrogate for the burden of LV fibrosis, and may 
allow the identification of early LV dysfunction83,84. 
GLS values are progressively more positive (i.e. less normal) as aortic stenosis 
severity worsens and are a strong predictor of cardiovascular mortality in patients 
with moderate or severe AS even after surgical intervention 83,85-87. A recent 
participant-level meta-analysis including over 1000 patients with significant AS and 
an LVEF >50% demonstrated that a GLS >-14.7% predicted poor survival in the 
overall cohort and amongst those individuals with an LVEF >60%88. 
Pulmonary hypertension
Key points
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 The echo report should include an assessment of the probability of pulmonary 
hypertension (PH) according to BSE guidelines97
 A high likelihood of PH should be highlighted to the referring clinician
There are relatively few published series in which echo-estimated pulmonary 
pressures have been examined in a cohort of patients with severe AS89-94. All are 
retrospective analyses, and deriving guidance is challenging, as a heterogeneous 
group of patients were included, many of who were already symptomatic or had 
other indications for intervention at the point of inclusion. Additionally, the 
echocardiographic methodology and threshold for defining important PH differed 
between reports, with some defining severe PH as an estimated PAP >50mmHg91-93, 
whereas others considered the threshold of severe PH as a PAP >60mmHg89,90. The 
most recent study used a methodology that attempts to reflect the current approach 
of estimating the probability of PH rather than directly estimating PAP94. All reports 
are consistent in that higher values of PAP are associated with poorer long-term 
survival, but the threshold that should trigger intervention remains unclear. 
Consequently, the BSE approach of assessing the probability of PH is appropriate for 
the AS cohort, and those individuals with a high probability of PH should be 
highlighted to the referring clinician95. 
11. Additional echocardiographic imaging modalities
Trans-oesophageal echocardiography
Key points
 TOE is rarely required for the assessment of AS
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 If TTE is insufficient, Doppler interrogation using TOE may confirm the severity 
of AS
TOE imaging windows are shown in Table 5. 
TOE is rarely required to assess aortic stenosis, but has use in the assessment of 
patients for TAVI. 3D TOE can facilitate accurate measurements of the aortic valve 
annulus and important characteristics such as proximity of the left main stem, 
combined with an assessment of calcification, and has been shown to provide 
equivalent information to that obtained by cardiac CT4,96-99. 2D TOE is not adequate 
for TAVI assessment as it may lead to undersizing of the TAVI implant owing to the 
elliptical nature of the LVOT and annulus99,100. 
Exercise stress echocardiography
Key points
 The BSE does not recommend the routine use of exercise stress 
echocardiography for the assessment of AS
Exercise testing (without echocardiography) is advocated in international guidance 
to unmask symptoms and identify patients with severe AS who may benefit from 
early intervention5. The value of exercise stress echocardiography is less clear-cut. 
Increases in the mean AVG and/or pulmonary pressures with exercise have both 
been examined in the context of severe AS, but there are contradictory reports as to 
whether they can identify patients at risk101-104. Consequently, the use of exercise 
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stress echocardiography in asymptomatic severe AS is no longer recommended in 
international guidance5,6.  
12. Special circumstances
Low-gradient AS
Most of the time, the clinical approach outlined in Figure 10 and Section 6, will allow 
the sonographer to classify the severity of AS and identify and highlight any high risk 
features to aid decision-making. 
However, in a significant minority of cases, the indices of aortic stenosis do not 
agree, which can present a challenge to the sonographer. There are several different 
reasons for this apparent disagreement (or discordance). The first is measurement 
error, and a priority when faced with such a scenario is to re-check all measurements 
and indices to ensure that accurate information has been obtained. 
The second explanation is that there is not a linear relationship between AV Vmax, 
mean gradient and AVA (see below). 
The final explanation relates to alterations in flow. Patients with reduced 
transvalvular flow will generate lower than expected Doppler indices for the 
observed severity of valve stenosis. The usual clinical example of this phenomenon is 
in the context of impaired LVEF, where poor systolic function means that gradients 
will be relatively low despite small aortic valve areas. This is low-gradient AS with 
impaired LVEF. In more recent times, it has been widely accepted that reduced 
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transvalvular flow can occur in patients with relatively normal LVEF (or at least an 
LVEF ≥50%).  This scenario is low-gradient AS with LVEF ≥50%. The echocardiographic 
approach to patients is very different when the LVEF is impaired compared to when 
it is ≥50%, and therefore it makes sense to address these patient groups separately. 
Low-gradient AS with LVEF ≥50%:
Key points
 This is defined as an AVA <1cm2; an AVAi <0.6cm2/m2; a mean AVG <40mmHg 
and an AV Vmax <4m/s
 The BSE approach is summarized in Figure 14
 Technical error explains a significant proportion of such findings. Optimal 
assessment of CW Doppler, LVOT flow and LVOT cross-sectional area will lead 
to many patients being re-classified as moderate AS
 Adverse outcomes are related to the presence of higher mean gradients, 
lower absolute AVA, increased indexed LV mass and low stroke volume
 An MDT approach to resolve challenging cases is advocated
Relationship between Doppler indices and AVA
There is not a linear relationship between AV Max, mean AVG and aortic valve area. 
The decision to make an AVA <1cm2 the cut-off for severe AS was largely arbitrary, 
and has led to a significant proportion of patients in whom the indices for severe AS 
apparently do not agree: prospective studies and large database analyses have 
shown that at least 25% of patients will have an AVA<1cm2, but a maximal AV 
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velocity (or mean AVG) that do not fulfil the criteria for severe AS. In fact, an AVA of 
0.8cm2 corresponds much better to the Doppler threshold of severe AS105,106. 
 
Given this knowledge, many ‘challenging cases’ can be resolved in a relatively 
straightforward manner. Very often the Vmax or mean gradient will fall in the range 
of 3.5-4m/s or 35-40mmHg respectively, at which point the AVA will likely be 
between 0.8-1.0cm2. In this scenario, the best study data supports such individuals 
as being labelled and treated as moderate AS5,30,38,41,42,107,108. Pragmatically such 
patients are often reported as ‘moderate to severe’ AS which is reasonable as they 
are approaching the point at which intervention may be considered, and this 
terminology helps to identify the advancing nature of the disease to the clinician. 
Where the apparent discrepancy is more overt: for example, if the mean AVG is 
<35mmHg or AV Vmax is <3.5m/s in the context of an AVA <1cm2, more 
consideration is required. 
Recommended approach (Figure 14)
 The first priority is to ensure that the valve is both heavily calcified and restricted. 
In the absence of these, significant AS is unlikely. 
 Re-evaluation of CW Doppler indices is essential. A common error is failing to 
insonate using the PEDOFF or standalone probe from multiple acoustic windows, 
at the very least from both the apex and the right parasternal window. See 
section 5 for the optimal methodology for obtaining CW traces. 
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 The CW waveform can sometimes provide clues as to the severity of the AS. A 
late peak of the CW trace with slow upstroke may indicate that the valve is truly 
severely stenosed (Figure 6).
 Optimal assessment of the PW trace is essential. Subtle changes in the positioning 
of the PW sample volume can make a dramatic difference in the assessment of 
the AVA (see Figure 15). 
 Consideration should be given to 3D planimetry of the LVOT cross-sectional area. 
The LVOT is often elliptical and the standard methodology of estimating the LVOT 
cross-sectional area will lead to an underestimation of stroke volume and an 
overestimation of AS severity using the continuity equation. Obtaining a 3D-image 
of the LVOT and directly tracing the LVOT cross-sectional area results in a 
substantial proportion of low-gradient severe AS patients being re-classified as 
moderate AS109 (see Figure 9). 
 If the above does not resolve the apparent discrepancy, the next stage is to 
evaluate the stroke volume index (SVi).
 An SVI ≥35ml/m2 is considered ‘normal’, whereas an SVi <35ml/m2 is considered 
‘low’110. 
 Patients with low-gradient AS and normal SVI (≥35ml/m2) have a prognosis 
similar to conventional ‘moderate AS’ and can usually be safely observed108. 
Prospective studies have shown that even in the presence of minor symptoms, 
such patients can have aortic valve intervention safely deferred until the mean 
AVG exceeds 40mmHg109. 
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 With low SVi (<35ml/m2), it is considerably more challenging to differentiate 
patients with truly-severe AS from those with non-severe AS. Additional ‘clues’ 
need to be obtained from the echocardiographic study in order to inform 
decision-making as to whether such patients are at lower or higher risk (Figure 
14). 
- - The presence of very low mean AVG (<30mmHg and certainly <25mmHg) 
makes severe AS unlikely111-113.
- - A mean gradient >30mmHg and certainly >35mmHg makes severe AS 
likely114,115. 
- The presence of increased indexed LV mass makes AS more likely115. 
 - An AVA <0.8cm2 makes severe AS more likely115. 
 - Clinical interpretation is important amongst this cohort. The presence of 
additional valve lesions, the presence of intrusive symptoms, clinical 
examination and co-existent coronary disease may influence decision-
making. 
 - An MDT approach should be considered for challenging cases. 
 - Although there are no prospective studies using CT calcium scoring to help 
identify true-severe AS amongst this cohort, CT may provide complimentary 
data to support clinical decision-making. 
 Some studies have supported the value of the valvulo-vascular impedance (Zva). 
Higher values of Zva are associated with poor cardiovascular outcomes, although 
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when co-morbidities are accounted for, the discriminatory value of Zva is limited 
and it is not useful in identifying patients who benefit from aortic valve 
intervention. Consequently, the BSE does not recommend Zva for routine use.
 Most patients with low-gradient AS will demonstrate progressive increase in AV 
Vmax and mean AVG with time and therefore warrant close clinical and 
echocardiographic follow-up. 
Flow rate assessment
There is increasing interest in the use of flow rate (FR) in aortic valve disease. Whilst 
FR shows promise, the current literature is insufficient to make robust guidance 
regarding its use in the cohort of low-gradient AS with LVEF ≥50%. Assessment of FR 
has theoretical benefits over the assessment of static volumes (i.e. the stroke 
volume index), but a lack of prospective studies means that, at the moment at least, 
it is not clear how patients should be managed if AS severity is defined according to 
the FR. It is not entirely clear what threshold of FR should be considered as normal, 
and given that FR is a non-indexed parameter, smaller individuals will necessarily 
have lower FR than larger individuals. Therefore the BSE currently does not 
recommend routine use of FR although acknowledges that it is an area of increasing 
interest. 
Complimentary imaging modalities – Cardiac CT
The use of CT in paradoxical low-gradient AS is reasonable, although there are no 
studies in which it has been used to guide intervention. It is important to appreciate 
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that significant valve obstruction may occur even in the absence of significant 
calcification, particularly in bicuspid or unicuspid valve disease. Finally, there is a 
large ‘grey zone’ of calcium scoring in which decision-making is not clear116. 
Low-gradient AS with impaired LVEF:
Key points
 This is defined as: an AVA <1.0cm2; an AVAi <0.6cm2/m2; a mean gradient 
<35mmHg; and an LVEF ≤40%
 The BSE approach is summarized in Figure 16
 After exclusion of technical error, such patients should be considered for 
dobutamine stress echocardiography (DSE)
 Conventional DSE and projected EOA should be combined in order to identify 
patients who may benefit from intervention
 CT calcium scoring can be considered if DSE provides an indeterminate result. 
 An MDT approach to resolve challenging cases is advocated
Background
In patients with a low cardiac output, recorded values for Vmax and mean gradient 
are lower than expected for the observed severity of AS, which could lead to 
individuals with severe AS being missed27,28,34,35. As the continuity equation is less 
flow-dependent than measured Vmax and mean gradient, it may be expected that 
an absolute AVA <1.0cm2 would reliably identify patients with severe AS28,34. 
Unfortunately, this is not the case. Whilst flow has minimal effect on the calculated 
valve area of severely stenotic valves, if a valve is only moderately stenotic, it retains 
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a considerable degree of compliance. A moderately stenotic valve will open 
relatively little in the presence of low stroke volume (and therefore have a small 
calculated valve area), but as cardiac output increases, the leaflets will open further, 
resulting in aortic orifice area that can be 30% larger34,35,117. Therefore an AVA 
<1.0cm2 is very sensitive but not sufficiently specific in differentiating truly severe 
aortic stenosis from a valve that is only moderately stenotic but appears severe 
owing to poor cardiac output (or pseudo-severe).  
DSE has been widely used and validated in this scenario to identify patients who may 
benefit from aortic valve intervention50,117-121. It is important to note exercise 
echocardiography does not elicit adequate augmentation of cardiac output and 
therefore should not be used in low-gradient AS with impaired LVEF122. 
Patient selection
DSE should usually be considered in patients with an AVA <1cm2; an AVAi 
<0.6cm2/m2; a mean gradient <35mmHg and an LVEF ≤40%. Patients with an LVEF 
≤40% but in the presence of high gradients (i.e. a mean AVG ≥35mmHg) should be 
considered for intervention without recourse to stress echocardiography.  
The BSE has diverged from international guidance with regards patient selection for 
DSE. Both American and European guidance advocate the use of DSE in patients 
when LVEF is up to 50%, although ESC guidance includes a caveat regarding stroke 
volume4,6. The BSE has chosen not to advocate this approach on the basis that in the 
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published literature essentially all patients undergoing DSE for low-gradient AS were 
observed to have an LVEF ≤40% (and very often ≤35%). 
Patients with an LVEF 41-49% but who do not fulfil all the criteria for severe AS 
therefore represent a challenging subset in which there is almost no data in the 
literature to provide robust guidance. The first priority is to re-evaluate the study to 
identify any technical error and confirm that the LVEF is not ≤40% (in which case DSE 
would usually be considered). Clearly a degree of clinical pragmatism is often 
employed in these scenarios: if a patient has an LVEF slightly higher that 40%, with 
an AVA <1cm2 but low mean gradient, it may be considered reasonable to undertake 
DSE. Conversely, a patient with an LVEF closer to 50%, with mean gradients of nearly 
40mmHg would usually be considered as having severe AS and DSE would not be 
warranted. Other clues such as the shape of the CW waveform may help to identify 
when a patient has severe vs. non-severe AS (Figure 6). There is some limited data in 
the literature regarding the use of flow rate (FR) in patients with an LVEF between 
41-49%. FR is obtained by dividing the stroke volume by the ejection time (see Figure 
17 for an example of how to calculate FR).  If FR is ≥200ml/s, the AVA appears to be 
an accurate assessment of AS severity and therefore such patients may be 
considered as having severe AS123. 
Finally, the clinical scenario may influence decision-making: for example if the 
patient was already being worked up for coronary revascularization, a heavily 
calcified aortic valve with at least moderate stenosis would usually warrant 
intervention thereby obviating the need for further detailed assessment of the valve. 
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This re-iterates the central role of the clinical MDT in decision-making for challenging 
or borderline cases.
Conventional Dobutamine Stress Echocardiography
Contractile reserve
Most individuals demonstrate an improvement of ≥20% in stroke volume with DSE, 
in which case they are considered to have ‘contractile reserve’. In these patients, 
repeating the assessment of the aortic valve at peak stress may demonstrate one of 
the following responses:
True-severe AS (TS-AS): A mean gradient that increases to ≥40mmHg, combined 
with an aortic valve area that remains <1cm2. Such patients have improved survival 
with AVR, whereas medical therapy results in dismal outcomes50,118.  
Pseudo-severe AS (PS-AS): The largest series (still only 29 patients) defined PS-AS as 
patients with an AVA at peak stress of ≥1.2cm2 combined with a mean gradient 
<40mmHg121. Such individuals appear to have outcomes similar to those of matched 
controls with LV impairment but without valve disease121. Despite being somewhat 
larger than the usual cut-off for severe AS, an AVA 1.2cm2 as a threshold for defining 
individuals with good outcomes under medical therapy is consistent with results 
from the TOPAS series (see below)117,119. 
No contractile reserve
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In around one third of patients, the stroke volume does not increase by ≥20%, i.e. 
there is no evidence of contractile reserve. In this circumstance, conventional DSE 
does not readily allow the clinician to differentiate TS-AS from PS-AS. Patients 
without contractile reserve demonstrate high peri-procedural mortality118,120,124, but 
routine medical therapy in such patients results in even worse survival120. Recent 
work from the TOPAS registry (see more below) indicate that individuals without 
contractile reserve have similar medium-term survival to those patients with 
contractile reserve after undergoing TAVI125,126. Given the increasing use of TAVI, 
with its associated reduction in peri-procedural risk, there is a clinical need to 
improve decision making within this cohort in particular.
Very low resting mean gradient
Very low resting mean gradients are strongly associated with high peri-operative 
mortality and apparent lack of benefit of aortic valve intervention118,120. Therefore 
‘truly-severe’ AS should be considered very unlikely in patients with resting mean 
aortic valve gradients of <20mmHg, and decisions to proceed to intervention made 
in an MDT environment. 
Projected flow area
In addition to the challenge of interpreting echo findings in patients without 
contractile reserve, a major difficulty with conventional DSE is that the contractile 
response of individual patients varies widely. For example: one patient may 
demonstrate a 50% increase in stroke volume, from 40mL to 60mL, whereas a 
different patient may only display a 20% increase, from 40mL to 48mL. Both would 
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be labelled as having ‘contractile reserve’, but it is obvious that the aortic Doppler 
indices obtained at peak stress would likely be very different, with only the first 
patient in the example improving stroke volume to that approaching normal. 
Projected flow area (EOA-Proj) is a concept whereby the clinician can use data 
obtained during DSE to predict what the aortic valve area would be at a ‘normal’ 
transvalvular flow rate. EOA-Proj was developed to help standardize the 
interpretation of DSE, and improve decision-making in patients without contractile 
reserve117,119,125,126. 
Methodology
EOA-Proj relies on the fact that an increase in transvalvular flow rate (and not just 
absolute stroke volume) will lead to changes in mean gradient and valve area34. If an 
individual undergoing DSE does not increase the transvalvular flow rate by ≥15%, the 
EOA-Proj is considered inaccurate and should not be used117,119. See Figure 17 for a 
worked example. 
Results of EOA-Proj
An EOA-Proj of <1.0cm2 is best at identifying TS-AS, and outperforms other resting 
and stress echo criteria117,119. Only individuals with an EOA-Proj of >1.2cm2 
performed well without AVR, consistent with the definition of PS-AS (above). 
Indeterminate result
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If conventional DSE does not elicit a contractile response, and the result of projected 
flow area is 1-1.2cm2 and/or the flow-rate fails to augment by ≥15%, the DSE 
outcome is indeterminate. In this scenario decision-making should be made in an 
MDT environment and complimentary imaging should be considered (see below).  
Complimentary imaging modalities – Cardiac CT
There is increasing interest in the use of cardiac CT in defining severity of AS and in 
particular scenarios where discordant indices are obtained116,127,128. The reported 
experience of a CT approach in patients with low-gradient AS with impaired LVEF is 
relatively small (fewer than 100 individuals in total), and aortic valve intervention 
was not guided by the results of CT findings. 
The value of a ‘negative’ CT calcium score within this cohort is not clear. CT cut-offs 
have been defined in order to identify patients who likely have an AVA <1cm2: 
However, the optimal threshold for pseudo-severe AS is 1.2cm2, on the basis that 
this higher AVA threshold identifies patients who perform well under medical 
therapy alone117,121. Using the standard CT threshold for severe AS therefore would 
risk some individuals being refused potentially beneficial intervention. As such, the 
BSE advises caution in the use of CT calcium scoring in the setting of low-gradient AS 
with impaired LVEF, and recommends that CT be employed only if DSE provides an 
indeterminate result. 
High gradient high valve area
Key points
Page 47 of 106 Accepted Manuscript published as ERP-20-0035.R2. Accepted for publication: 11-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/16/2021 09:24:48AM
via free access
 High gradient-high valve area (HGHA) is defined as patients with a mean 
gradient ≥40mmHg, and an AVA ≥1cm2
 HGHA is rarely seen in routine practice
 The HGHA cohort should be carefully assessed for measurement error, 
particularly regarding the LVOT cross-sectional area
 HGHA patients should be considered as having severe AS
The clinical scenario where Vmax and mean AVG are high (implying severe stenosis) 
but AVA >1cm2, consistent with only moderate AS, is seen rarely, with an estimated 
prevalence of 1%105. To the BSE’s knowledge, there has been no systematic 
echocardiographic analysis of such patients, with current guidance based upon 
findings from CT studies. All HGHA patients have high CT calcium levels, and 
accordingly current guidelines suggest that such patients should be treated as severe 
AS4,116,128. 
13. Combined valve disease
There is a paucity of data in the literature regarding multiple valve disease, despite 
the fact that the combination of one or more valve lesion occurs relatively 
frequently2,129,130. The over-riding principle is that there should be a comprehensive 
assessment of all valvular lesions, evaluated according to specific guidance. 
Aortic stenosis and aortic regurgitation
Key points
Page 48 of 106Accepted Manuscript published as ERP-20-0035.R2. Accepted for publication: 11-Mar-2021
Copyright © 2019 the authors Downloaded from Bioscientifica.com at 03/16/2021 09:24:48AM
via free access
 When both AS and aortic regurgitation (AR) are at least moderate in severity, 
the lesion should be reported as ‘mixed aortic valve disease’ 
 AVA is not a useful marker of prognosis in mixed aortic valve disease
 Grading of mixed aortic valve disease should be guided by the AV Vmax: 
- Moderate mixed aortic valve disease (Vmax 3-3.9m/s)
- Severe mixed aortic valve disease (Vmax 4-4.9m/s)
- Very severe mixed aortic valve disease (Vmax ≥5m/s)
Mixed aortic valve disease is a commonly encountered clinical scenario, partly as the 
dominant causes of aortic stenosis are similarly important aetiological factors in 
aortic regurgitation (AR)4. 
In the case of mixed aortic valve disease, reporting the severity is challenging. For 
example: the rationale for describing a valve lesion as ‘moderately severe’ is that it 
provides the clinician with information as to the likely prognosis. An 
echocardiographic report stating ‘moderate AS and moderate AR’ may be deceptive, 
as the prognosis of this combination of valve lesions is more in keeping with isolated 
severe AS129. 
Some principles are important. Mild AR does not impact upon the assessment of 
aortic stenosis. However, as the severity of AR increases, the stroke volume will also 
become larger. AV Vmax and mean gradient are proportional to stroke volume, and 
therefore in the presence of moderate or worse AR, higher values of AV Vmax and 
mean gradient will be observed relative to the aortic valve area. Given that the 
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assessment of AVA using the continuity equation corrects for alterations in flow, it 
may be assumed that AVA is a better tool in the assessment of AS in the context of 
co-existent AR. 
In fact, the prognosis of patients with combined AS and AR is far more closely linked 
to the maximal AV velocity, which reflects the overall haemodynamic load on the left 
ventricle129. In patients with mixed AV disease, event-free survival is the same for 
those individuals with a calculated AVA of <1cm2 as it is for patients with an AVA 
between 1-1.5cm2, whereas there is a step-wise deterioration in outcomes as AV 
Vmax is seen to increase129. The average time-to-event with mixed aortic valve 
disease closely resembles the event curves of lone AS when patients are divided 
according to AV Vmax30,38,39,129. The conventional approach of intervening on the 
valve when the patient fulfils an accepted guideline criteria for surgery (for either AR 
or AS) appears appropriate and does not result in excess mortality129. 
Aortic stenosis and mitral regurgitation
Key points
 With combined AS and mitral regurgitation (MR) a detailed assessment of 
both valve lesions is mandatory
 In the presence of severe MR, AV Vmax and mean gradient may 
underestimate the severity of AS
 AVA is a more accurate assessment of AS severity in the presence of 
significant MR
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 If co-existent MR severity is more than mild, TOE is recommended to clarify 
the severity and mechanism of mitral regurgitation
The combination of AS and mitral regurgitation (MR) is seen frequently, particularly 
in older populations130. In the case of severe MR, forward stroke volume will be 
reduced. This may lead to an underestimation of AS severity when relying on the 
Vmax and mean gradient, whereas AVA is more reflective of true AS severity. 
In such patients a comprehensive assessment of both valve lesions should be 
completed. Timing of intervention is informed by international guidelines5,6. In 
particular a detailed assessment of the mechanism of mitral regurgitation should be 
obtained as this may provide clues as to whether the MR will improve simply by 
intervening on the aortic valve, or whether dual valve intervention is needed130. 
Aortic stenosis and mitral stenosis
Key points
 Co-existent severe MS may result in an underestimation of AS severity using 
AV Vmax and mean gradient
 AVA is a more accurate assessment of AS severity in the presence of 
significant MS
Patients with severe mitral stenosis will have low stroke volume, and the presence of 
severe MS is a well-recognised cause of low-gradient AS. The AVA provides a better 
assessment of true AS severity in this scenario131. In patients undergoing surgery for 
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MS it is recommended that detailed assessment of the aortic valve be completed to 
ensure that low-gradient AS is not present, which may necessitate aortic valve 
replacement at the time of surgery. 
14. Aortic stenosis and amyloid
Key points
 There is an important association between amyloid and advanced AS in older 
patients
 Patients with combined amyloid-severe AS still derive benefit from AV 
intervention
 Echocardiographic features of amyloid including high LV mass and changes in 
GLS are not specific for amyloid in a population of severe AS
Recent work has demonstrated an important association between aortic stenosis 
and cardiac amyloid in an older population132-135. Whilst the overall prevalence of 
cardiac amyloid in individuals over 80 years of age is considered to be around 3%, in 
prospective studies of patients with severe AS referred for TAVI, the observed 
prevalence of amyloid was considerably higher, with estimates varying between 13-
16% of such cases133,135. 
The value of echocardiography in identifying patients with combined amyloid-severe 
AS is not clear. GLS is frequently low in such patients but the pattern of ‘apical 
sparing’ is not specific for amyloid in this cohort and is often seen in individuals with 
isolated severe AS133,135. Consistently, average mitral annular S’ appears to be lower, 
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and LV mass marginally higher in patients with combined amyloid-severe AS. Non-
echo findings that may hint toward the existence of amyloid include the presence of 
RBBB on the ECG and raised biomarkers. Owing to the prevalence of abnormal 
myocardial systolic and diastolic function in older patients with advancing AS, no 
echocardiographic or clinical feature can be considered as a reliable method to 
differentiate a patient with combined amyloid-severe AS from someone with 
isolated severe AS133,135. 
An early retrospective analyses suggested that patients with combined amyloid-
severe AS had worse survival than equivalent patients with isolated AS132. However, 
recent prospective studies in which all participants referred for TAVI underwent 
diagnostic testing have shown that individuals with combined amyloid-severe AS do 
not have demonstrably poorer survival and derive as much benefit from aortic valve 
intervention as those individuals with isolated severe AS133,135. 
The caveat is that these recent works have only screened patients with severe AS 
who were referred for consideration of intervention. The prevalence, pattern, and 
outcomes of patients with non-severe AS combined with amyloid is not well 
established. 
Therefore, the approach advocated throughout this guideline should be followed in 
all patients. The primary focus should be toward optimization of the 
echocardiographic assessment and classifying the severity of AS, before identifying 
any high-risk characteristics. All patients should undergo a comprehensive 
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echocardiographic assessment according to the principles of the minimum dataset3. 
Whilst the classical echocardiographic features of amyloid may not be specific for 
the disease in patients with severe AS, when aortic stenosis is mild or even 
moderate, the usual echocardiographic approach for identifying infiltrative disease is 
appropriate. 
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Figure Legends:
Figure 1: Normal anatomy. Parasternal long axis window (a and b), with zoom images (c and 
d). M-mode recording of the aortic valve should be obtained with the cursor perpendicular 
to the axis of the aorta (e). Normal M-mode trace (f): note central closure line (labelled). 
Anatomy of the aorta (g). Image (h) marks the insertion of the cusps (red dotted line) and 
sino-tubular junction (green dotted line). Parasternal short axis window at the level of the 
aortic cusps (images i and j). Image (k) represents a zoomed image of the aortic valve during 
systole with the three cusps labelled. In image (l), the lines represent potential parasternal 
long axis imaging planes. Whilst both transect the right coronary cusp, it is evident that a 
subtle change in angle of the transducer will lead to inclusion of either the non-coronary 
cusp (red dotted line) or left coronary cusps (green dotted line). 
Figure 2: Bicuspid aortic valve. In the top panes there are images of a bicuspid valve with 
right-left (RL) configuration (annotated; systole (a) and (b) diastole). Images (c) and (d) 
depict a bicuspid valve with anterior-posterior configuration (AP) with a raphe in the 
anterior cusps (marked with asterisk). M-mode recording of a bicuspid valve with AP 
configuration (e): note eccentric closure line (marked with asterisk). Image (f) depicts a 
calcified aortic valve obtained using TOE, which appears tricuspid. Colour Doppler is applied 
in image (g) and demonstrates a ‘crescent-shaped’ opening indicating this is a bicuspid valve 
(AP configuration with raphe). 
Figure 3: Parasternal long axis window of a unicuspid aortic valve during diastole (a) and 
systole (b). Note the marked ‘doming appearance’ during systole. Parasternal short axis 
window during diastole (c) and systole (d): note how the orifice is eccentric. This valve has 
minimal calcification and retains mobility. Image (e) represents CW Doppler through the 
unicuspid valve. There is obstruction to flow despite the lack of calcification. 
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Figure 4: Haemodynamic considerations of AS. In a patient with severe AS, blood flow 
accelerates prior to the valve (flow acceleration region marked). The jet contracts in order to 
fit through the anatomical orifice and continues to contract for a short period, forming the 
effective orifice. Doppler indices of AS measure the severity of obstruction at the level of the 
effective orifice. In the ascending aorta, there is a degree of ‘pressure recovery’.
Figure 5: Assessment of maximal AV velocity and mean gradient using CW Doppler. CW 
tracings should be obtained from multiple echocardiographic windows: suprasternal window 
(a), with corresponding Doppler in (b); subcostal (c) and (d); apical 5-chamber (e); and stand-
alone probe from the right parasternal window (f). Note that the AV Vmax in (e) represents 
significant underestimation of maximal velocity when compared to that obtained using the 
standalone probe (f). Images (g) and (h) demonstrate spectral dispersion of the CW Doppler 
trace (marked with an asterisk). The mean gradient is obtained from tracing around the 
dense part of the CW Doppler curve. In images (i) and (j), the CW trace has been optimised: 
in (i) some spectral dispersion remains, but this has been completely eliminated in (j), 
resulting in an ideal CW trace. 
Figure 6: Comparison of the shape of the CW waveform. On the left, a patient with 
moderate AS: note how there is a rapid acceleration and an early peak. For comparison, the 
patient on the right has severe AS. There is a slower acceleration with a late peak. The shape 
of the CW waveform is maintained irrespective of LVEF and therefore it may be useful to 
help identify severe AS in difficult scenarios such as low-gradient AS.
Figure 7: Optimal assessment of the LVOT Doppler. The PW Doppler sample volume should 
initially be placed on the aortic valve (a), which will usually result in aliasing. It should then 
be slowly moved apically (i.e. away from the valve; images b and c). In (c) there is a wide 
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area of density at the apex of the trace, evident in the zoomed image (e; marked with 
asterisk). This represents blood flow within the zone of acceleration immediately proximal to 
the valve, and should not be included, as it would result in an overestimation of LV stroke 
volume and an underestimation of AS severity. In (d), (f), (g) and (h) the trace has been 
optimised further and depicts ideal assessment of LVOT Doppler. When tracing the curve, 
any spectral dispersion should be ignored (marked in (g) with a +). Three traces should be 
obtained and averaged for use in the continuity equation, with sweep speed set between 
50-100mm/s (h)
Figure 8: Eccentric calcification can lead to important underestimation of LVOT diameter, 
here demonstrated with 3D imaging. Figure (a) depicts a long-axis view obtained during TOE 
with LVOT diameter marked (red dotted line). Picture (b) is an image of the LVOT taken at an 
orthogonal plane to image (a). Note that the LVOT diameter is an underestimate owing to 
two areas of eccentric calcification (marked). Adjustment of the imaging plane can remove 
calcification from the image (c), with the optimal LVOT diameter now shown (red dotted line 
in images c and d). 
Figure 9: Error arising from assumption of circular LVOT. Image (a) depicts a long-axis view of 
the aortic valve obtained using 3D TOE. The LVOT diameter has been measured 2cm 
proximal to the valve (red dotted line). Image (b) is a short axis image obtained at this 
anatomical level. Estimation of the LVOT cross-sectional area at this point calculates the area 
of the red dotted circle, and is a huge underestimate of the ‘true’ LVOT area (marked by blue 
dotted outline). The LVOT should be measured immediately below the insertion of the aortic 
cusps (c; green dotted line). Image (d) depicts the short axis view at this anatomical level: 
note the LVOT demonstrates a much more circular profile. Estimation of the LVOT area using 
π (LVOTd ÷ 2)2  would calculate the area of the green dotted circle, which is much closer to 
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the ‘true’ LVOT area (blue dotted line). On occasion, direct planimetry of the LVOT cross-
sectional area using 3D echo can be considered, particularly for difficult cases (see low-
gradient AS, section 12). 
Figure 10: Decision-aid to guide assessment of aortic stenosis. 
Figure 11: Planimetry using 3D TOE. A 3D volume of the aortic valve is obtained (a). The 
volume can be manipulated to display orthogonal planes. Image (b) depicts a long-axis view, 
and the dotted red line depicts the plane from which a short axis view (c) is then shown. This 
plane is aligned with the point of insertion of the valve cusps. In (d), the image has been 
manipulated, and the ‘plane of interest’ moved further into the aorta such that it now aligns 
with the valve tips (dotted green line). The short axis window obtained at the level of the 
dotted green line is displayed in image (e). Planimetry obtained in image (c) clearly 
overestimates aortic valve orifice area when compared to the result obtained by planimetry 
in image (e). 
Figure 12: Worked example of the energy-loss index (ELI):
• From the image (a), the LVOT cross-sectional area can be calculated:
LVOT CSA = π x (LVOTd ÷ 2)2 =3.5cm2
• The cross-sectional area of the ST junction (STJ) depicted in image (b) is:
STJ CSA = π x (STJ diameter ÷ 2)2 = 6.6cm2
• Using the CW trace in image (c), AV Vmax is 3.1m/s; mean gradient 27mmHg; AV VTI 
55cm. Using the PW trace in image (d), LVOT VTI is 14cm.
• Aortic valve area using the continuity equation is:
AVA = LVOT VTI ÷ AV VTI x LVOT CSA = 14cm ÷ 55cm x 3.5cm2 = 0.9cm2
• After indexing for BSA (1.7m2 in this patient), the AVAi is 0.51cm2/m2
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• This is an example of low-gradient AS whereby both the AVA and AVAi suggest severe 
stenosis yet the AV Vmax and mean gradient only suggest moderate stenosis.
• The energy-loss index is defined as:
ELI = (AVA x STJ CSA) ÷ (STJ CSA – AVA) 
ELI = (0.9 x 6.6) ÷ (6.6 – 0.9) = 1.04cm2
Indexed for BSA = 0.61cm2/m2
• An ELI <0.6cm2/m2 is consistent with severe AS, therefore this patient has been re-
classified as moderate AS when accounting for the pressure-recovery phenomenon.
Figure 13: Assessment of Doppler indices and AVA in AF. Doppler traces obtained from a 
patient in AF (a and b): note marked beat-to-beat variations of the CW and PW waveforms. 
Conventionally, at least 5-10 consecutive CW and PW traces are obtained for assessment of 
valve indices (a and b). An alternative method is the ‘matched R-R interval’ approach: in 
image (c) the R-R interval is seen as 600ms, and the CW waveform is traced. In image (d) a 
comparable PW waveform is found, whereby the R-R interval is noted to be 607ms, and is 
therefore traced. The obtained values from these comparable CW and PW traces can be 
used in the continuity equation. Within CW traces it is possible to appreciate a ‘phantom’ 
LVOT trace (e). The true LVOT trace is displayed in image (f) for comparison. This phantom 
trace should not be used for the continuity equation, as it will directly lead to an 
underestimation of AS severity.
Figure 14: Summary of recommendations for low-gradient AS with LVEF ≥50%. 
Figure 15: Example of technical error resulting in low-gradient AS. A patient was noted to 
have calcified restricted aortic valve. The LVOTd is 2.0cm (not shown). The LVOT cross 
sectional area is 3.14cm2. PEDOFF values from the apical 5-chamber window demonstrate 
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an AV Vmax 3.5m/s; mean gradient 30mmHg; AV VTI 71cm (a). If the PW sample volume is 
placed as in image (b), corresponding Doppler traces are shown in (d). This leads to an 
estimated AVA of 0.8cm2, consistent with low-gradient severe AS. In image (c), the PW 
sample volume has been moved closer to the valve, with corresponding Doppler trace in (e): 
note the amplitude of the traces is significantly larger. This leads to an estimated AVA of 
1.1cm2, consistent with moderate AS. 
Figure 16: Summary of recommendations for DSE in low-gradient AS with impaired LVEF. 
Figure 17: Worked example of the projected EOA methodology:
• A patient with severe LV impairment was noted to have calcified restricted aortic valve (a). 
The LVOTd is 2.2cm (b). The LVOT cross sectional area is 3.8cm2. 
• Optimal CW and PW recordings were obtained from the 5-chamber window (c and d). AV 
Vmax 2.4m/s; mean gradient 16mmHg; AV VTI 50cm (e); LVOT VTI 9cm. 
• AVA at rest calculated using the continuity equation:
AVArest = LVOT VTI ÷ AV VTI x LVOT CSA = 9cm ÷ 50cm x 3.8cm2 = 0.68cm2
• Flow at rest (Qrest) is calculated from the stroke volume and the ejection time (f):
Qrest = stroke volume ÷ ejection time = 9cm x 3.8cm2 ÷ 0.36s = 95ml/s
• At maximal stress, CW Doppler was obtained (g): AV Vmax 3.2m/s; mean gradient 
28mmHg; AV VTI 61cm. PW Doppler at peak stress (h): LVOT VTI 16cm; ejection time was 
0.33ms. The LVOTd is assumed to remain unchanged with stress.
AVApeak = LVOT VTI ÷ AV VTI x LVOT CSA = 16cm ÷ 61cm x 3.8cm2 = 1.0cm2
Qpeak  = stroke volume ÷ ejection time = 16cm x 3.8cm2 ÷ 0.33s = 184ml/s
• Note that the stroke volume has increased by >20% and therefore the patient has 
contractile reserve.
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• The mean gradient has only increased to 28mmHg, and therefore this patient does not 
fulfil the criteria for ‘true-severe AS’. Equally, the patient has not fulfilled the usual criteria 
for ‘pseudo-severe’ AS, which mandates an AVA ≥1.2cm2 at peak stress. 
• The projected-EOA calculates the AVA at a ‘normal’ transvalvular flow rate of 250ml/s:
Projected EOA = AVArest + ((AVApeak – AVArest) ÷ (Qpeak  - Qrest) x (250-Qrest))
Projected EOA = 0.68 + ((1.0 – 0.68) ÷ (184-95) x (250-95)) > 1.2cm2
• An EOA-Proj>1.2cm2 is consistent with ‘pseudo-severe AS’. This patient should therefore 
be treated medically. 
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Table 1. Subsections of the BSE aortic valve guidance
1. Anatomy
- Standard anatomy and imaging planes
- Variant anatomy
2. Calcification and aetiology of AS
3. Haemodynamic principles of AS
4. Standard echocardiographic images 
5. Essential parameters in the echocardiographic assessment of AS severity
- Aortic valve maximal velocity (AV Vmax)
- Mean aortic valve gradient (mean AVG)
- Aortic valve area (AVA)
- Potential sources of error and troubleshooting 
6. Approach to the patient
7. Grading of severity
- Aortic sclerosis
- Mild, moderate and severe AS
- Very severe AS
8. Additional parameters to define severity
- Indexed aortic valve area (AVAi)
- Dimensionless index
- Planimetry




10. Additional prognostic markers
- Left ventricular ejection fraction
- Indexed Left ventricular mass
- Global longitudinal strain
- Pulmonary hypertension
11. Additional echocardiographic imaging modalities
- Trans-oesophageal imaging
- Exercise stress echocardiography
12. Special circumstances
- Low-gradient AS with LVEF ≥50%
- Low-gradient AS with impaired LVEF
- High gradient high valve area
13. Combined valve disease
- Aortic stenosis and aortic regurgitation
- Aortic stenosis and mitral regurgitation
- Aortic stenosis and mitral stenosis
14. Aortic stenosis and amyloid
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Table 2: Standard TTE images for the assessment of AS
View 






indexed LV mass 
using linear 
method
Visual assessment of wall 
motion. 
Calcification of aortic 
valve (see section 2)
Indexed LV mass is a 
prognostic marker in AS 
(section 10)
Parasternal 
long axis; zoom 
2D
Assess calcification and 
mobility of cusps.
Advanced AS unlikely 
without significant cusp 
calcification or restriction.
Assess for central vs. 
eccentric closure line 
suggesting BAV (section 
1)
Parasternal 
long axis; zoom 
2D with colour 
Doppler
Assess for turbulence and 
presence of aortic 
regurgitation 
Parasternal 








Inner-edge to inner-edge 
in mid-systole when LVOT 
is at a maximum
Measurement parallel to 
aortic valve
See section 5
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Parasternal 
long axis; zoom 
2D
Measurement 




Inner-edge to inner-edge 
method in end-diastole
May be used in 
assessment of the energy 






Visual appearance of 









Visual appearance of 
calcification and 
mobility of cusps
Colour Doppler to 
assess for presence 











LVEF is a prognostic 
marker in AS (See 
section 10)
GLS is a potential 
marker of prognosis in 







Visual appearance of 
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tracings for AV 




Trace around dense 
aspect of Doppler curve
Average of three tracings 
in sinus rhythm (SR).
See section 5 for 













Trace around modal 
velocity
Average three tracings in 
SR. 
See section 5 for 













LVEF is a prognostic 
marker in AS (See section 
10)
GLS is a potential marker 









Calcification and mobility 
of aortic valve
+ colour Doppler for 
assessment of AR
Consider GLS (see section 
10)
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+ repeat CW 
and PW 
Doppler
Mobility and calcification 
of valve
Repeat Doppler tracings 






Look for turbulence and 
aortic pathology 
Repeat CW Doppler for 






Distal arch / descending 
aorta. Look for 










AV Vmax and 
mean gradient
Repeat from all imaging 
windows to ensure 
maximal values of Vmax 
and mean gradient are 
obtained
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tracings for AV 




Trace around dense 
aspect of Doppler 
curve
Average of three 
tracings in SR.














Trace around modal 
velocity
Average three tracings 
in SR













LVEF is a prognostic 
marker in AS (See 
section 10)
GLS is a potential 
marker of prognosis in 









mobility of aortic valve
+ colour Doppler for 
assessment of AR
GLS assessment (see 
section 10)
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Look for turbulence 
and aortic pathology 
Repeat CW Doppler 
for AV Vmax and 






Distal arch / 
descending aorta. 











AV Vmax and 
mean gradient
Repeat from all 
imaging windows to 
ensure maximal 
values of Vmax and 
mean gradient are 
obtained
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Table 3: Suggested reporting template for AS
Demographics
- Height, weight, body surface area (BSA).
- Blood pressure, heart rate and rhythm. 
Aortic valve morphology
- Tricuspid / bicuspid / unicuspid
- Severity and extent of calcification
LVOT
- Dimensions and VTI
- Report any change in the LVOTd from previous studies
Aortic stenosis severity
- Aortic valve Vmax; mean gradient: include window from which maximal values 
were obtained
- Change in AV Vmax from previous echo study
- Aortic valve area
- Description of severity (mild / moderate / severe / very severe)
Additional prognostic markers
- Left ventricular ejection fraction
- Global longitudinal strain
- Indexed LV mass
- High probability of pulmonary hypertension (see specific BSE guidance)
Aortic regurgitation – note presence and severity (see specific BSE guidance)
Aorta – measure size (see specific BSE guidance and reference intervals)
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Table 4: Grading of aortic stenosis
Echocardiographic indices





Aortic sclerosis <2.5 m/s - -
Mild 2.5-2.9m/s <20 mmHg >1.5 cm2
Moderate 3-3.9m/s 20-39 mmHg 1-1.5 cm2
Severe 4-4.9m/s 40-59 mmHg <1 cm2
Very severe ≥5m/s ≥60 mmHg ≤0.6 cm2
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Table 5: TOE imaging in aortic stenosis
View 














zoom 2D + 
colour Doppler
Colour Doppler 
imaging to assess for 






60°; the level of 
the aortic cusps 
2D








60°; at the level 
of the aortic 
cusps 2D zoom 
+ colour 
Doppler
 Assess for AR
Colour Doppler may 
help identify 
morphology (shown is 
tricuspid valve; see 
section 1)
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3D dataset Consider planimetry
Overview and 














and mobility of the 
cusps. 
LV size and function












Inner-edge to inner 
edge method; end-
diastole
Red = Sinus of Valsalva




window; 0°; at 
the level of the 
aortic cusps 2D 
+ colour 
Doppler
Manipulation of probe 
to ‘open’ aortic valve 
(marked with ‘A’)
Assessment of 










 Assess for AR 
Colour Doppler may 
help identify 
morphology (shown is 
tricuspid valve; see 
section 1)
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attempt at all 
angles); CW 
Doppler
AV Vmax and 
mean gradient
Trace round modal 
velocity




attempt at all 
angles); PW 
Doppler




Trace round modal 
velocity
See section 5 for 
details
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